IP Library › Granted Patent US 12,636,408
Granted Patent B2
US 12,636,408 · App. 17/887,013 · Granted May 26, 2026

Adipose compositions and methods of use thereof

Inventor: Alla Danilkovitch (Columbia, MD)
Assignee: BRITECYTE INC.
A61L27/3691
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,636,408
App. No.
17/887,013
Granted
May 26, 2026
Kind
B2
Abstract

Disclosed are devitalized adipose tissue. Disclosed are compositions comprising devitalized adipose tissue. In some aspects, the compositions further comprise a cryopreservation or lyophilization solution. Disclosed are cryopreserved or lyophilized devitalized adipose tissue. Disclosed are methods of augmenting a soft tissue site of a subject in need thereof comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having fat pad atrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having lipodystrophy comprising administering to the subject a composition comprising devitalized adipose tissue. Disclosed are methods of treating a subject having a metabolic disease or condition comprising administering to the subject a composition comprising devitalized adipose tissue.

Claims (18)

1 . A composition comprising devitalized adipose tissue and trehalose,

wherein the devitalized adipose tissue is not decellularized,

wherein the devitalized adipose tissue comprises at least 50% of native lipids,

wherein the composition does not comprise free lipids, and

wherein the devitalized adipose tissue comprises less than 5% native viable cells.

2 . The composition of claim 1 , wherein the devitalized adipose tissue is minced.

3 . The composition of claim 2 , wherein the minced devitalized adipose tissue comprises pieces of adipose tissue less than 1 mm in size.

4 . The composition of claim 1 , wherein the devitalized adipose tissue comprises at least 70% native growth factors.

5 . The composition of claim 1 , wherein the devitalized adipose tissue retains its native structure.

6 . The composition of claim 1 , further comprising a pharmaceutically acceptable carrier.

7 . The composition of claim 1 , wherein the devitalized adipose tissue is cryopreserved or has been previously cryopreserved.

8 . The composition of claim 1 , wherein the devitalized adipose tissue is lyophilized or has been previously cryopreserved.

9 . The composition of claim 1 , further comprising human serum albumin.

10 . The composition of claim 1 , wherein the devitalized adipose tissue comprises less than 5%, 2%, 1%, 0.5%, 0.2%, 0.1%, 0.05% or 0.01% peroxidized lipids of total lipids.

11 . A method of augmenting a soft tissue site of a subject in need thereof comprising administering to the subject the composition of claim 1 .

12 . A method of treating a subject having fat pad atrophy comprising administering to the subject the composition of claim 1 .

13 . A method of treating a subject having lipodystrophy comprising administering to the subject the composition of claim 1 .

14 . A method of treating a subject having a metabolic disease or disorder comprising administering to the subject the composition of claim 1 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2023
From: DANILKOVITCH, ALLA
To: BRITECYTE INC.
Reel/Frame 062691/0309 →
Continuity (2)
Provisional Application 63232465 · Aug 12, 2021
Related Publication 20230063467A1 · Mar 2, 2023
References Cited (48)
US 7890183B2 · Palti · 2011 [cited by applicant]
US 10596201B2 · Huang · 2020 [cited by applicant]
US 20080195230A1 · Quijano · 2008 [cited by applicant]
US 20100279405A1 · Peterson · 2010 [cited by examiner]
US 20110008300A1 · Wouters · 2011 [cited by examiner]
US 20110151011A1 · Flynn · 2011 [cited by applicant]
US 20120264190A1 · Christman · 2012 [cited by applicant]
US 20140234272A1 · Vesey · 2014 [cited by applicant]
US 20150044179A1 · Saeki · 2015 [cited by applicant]
US 20160101200A1 · Chitre · 2016 [cited by examiner]
US 20170021058A1 · Huang et al. · 2017 [cited by applicant]
US 20180117088A1 · Cao et al. · 2018 [cited by applicant]
US 20180127719A1 · Nahas et al. · 2018 [cited by applicant]
US 20190076582A1 · Connor · 2019 [cited by applicant]
US 20190111183A1 · Xu · 2019 [cited by applicant]
US 20190298885A1 · Schilling · 2019 [cited by applicant]
US 20220032934A1 · Zhang · 2022 [cited by applicant]
US 20220073881A1 · Nahas · 2022 [cited by applicant]
US 20220339196A1 · Rho et al. · 2022 [cited by applicant]
US 20230044236A1 · Kim · 2023 [cited by applicant]
US 20230063467A1 · Danilkovitch · 2023 [cited by applicant]
US 20240261471A1 · Danilkovitch · 2024 [cited by applicant]
WO WO2021045595A1 · 2021 [cited by applicant]
WO WO2023287892A1 · 2023 [cited by applicant]
Cheung et al., Composite hydrogel scaffolds incorporating decellularized adipose tissue for soft tissue engineering with adipose-derived stem cells, Biomaterials, vol. 35, (2014), pp. 1914-1923. [cited by examiner]
Bush-Joseph et al., Effect of Tibial Attachment Location on the Healing of the Anterior Cruciate Ligament Freeze Model, Journal of Orthopaedic Research, vol. 14, (1996), pp. 534-541. [cited by examiner]
Flynn, The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells, Biomaterials, vol. 31, (2010), pp. 4715-4724. [cited by examiner]
U.S. Appl. No. 63/232,465, filed Aug. 12, 2021, Danilkovitch. [cited by applicant]
U.S. Appl. No. 63/221,248, filed Jul. 17, 2022, Danilkovitch. [cited by applicant]
PCT/US22/36982, Oct. 4, 2022, Danilkovitch. [cited by applicant]
International Search Report and Written Opinion mailed on Oct. 5, 2022 by International Searching Authority for Patent Application No. PCT/US22/36982, which was filed on Jul. 13, 2022 (Inventor—Danilkovitch et al.; Appl… [cited by applicant]
Rossi. “Decoration of RGD-mimetic porous scaffold with engineered, devitalized adipose matrix.” Acta Biomaterialia. Dec. 18, 2016, p. 192. [cited by applicant]
Chun, S.Y., et al., “Optimization of extracellular matrix extraction from human perirenal adipose tissue,” Journal of Biomaterials, 35(9): 1180-1191 (2021). [cited by applicant]
Chun, S.Y., “Optimal delipidation solvent to secure extracellular matrix from human perirenal adipose tissue,” Journal of Biomedical Materials Research, (2021), Abstract. [cited by applicant]
Flynn, L.E., “The use of decellularized adipose tissue to provide an inductive microenvironment for the adipogenic differentiation of human adipose-derived stem cells,” Biomaterials, 31(17): 4715-4724 (2010). [cited by applicant]
Guo, L., et al., “Comparison of adipose tissue cellularity in chicken lines divergently selected for Fatness,” Poultry Science, 90(9): 2024-2034 (2010). [cited by applicant]
Moon, J., et al., “Brown adipose tissue ameliorates autoimmune arthritis via inhibition of Th17 cells,” Scientific Reports, 10:12374 (2020). [cited by applicant]
Niazli, N., “Autologous Micro Fragmented Adipose Cell Therapy for End-Stage Ankle Osteoarthritis—Case Report and Review of Literature,” SN Comprehensive Clinical Medicine, 3: 909-913 (2021). [cited by applicant]
Vargel, I., et al., “Autologous Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF) for Knee Osteoarthritis,” Int. J. Mol. Sci., 23: 13517 (2022), 32 Pages. [cited by applicant]
Wang, L., et al., “Combining decellularized human adipose tissue extracellular matrix and adipose-derived stem cells for adipose tissue engineering,” Acta Biomaterialia, 9(11):8921-8931 (2013). [cited by applicant]
Wang, J.K., et al., “Supercritical carbon dioxide extracted extracellular matrix material from adipose tissue,” Materials Science and Engineering, C75: 349-358 (2017). [cited by applicant]
Wu, I., et al., “An Injectable Adipose Matrix for Soft Tissue Reconstruction,” 129(6): 1247-1257 (2012). [cited by applicant]
Kim, D.Y., et al., “Cryopreservation of lipoaspirates: in vitro measurement of the viabiity of adipose-derived stem cell and lipid peroxidation,” Int. Wound J., pp. 1-9 (2020). [cited by applicant]
Menzi, N., et al., Wet milling of large quantities of human excision adipose tissue for the isolation of stromal vascular fraction cells, Cytotechnology, 70: 807-817 (2018). [cited by applicant]
Osinga, R., et al., “Effects of Intersyringe Processing on Adipose Tissue and Its Cellular Components: Implications in Autologous Fat Grafting,” Plastic and Reconstructive Surgery, 135(6): 1618 (2015). [cited by applicant]
Rao, P., et al., “Structural and Functional Characterization of Deceased Donor Stem Cells: A Viable Alternative to Living Donor Stem Cells,” Hindawi, Stem Cells International, 13 Pages (2019). [cited by applicant]
Schafer, M.E., et al., “Acute Adipocyte Viability After Third-Generation Ultrasound-Assisted Liposuction,” Aesthetic Surgery Journal, 33(5): 698-704 (2013). [cited by applicant]
Urbonas, T., et al., “Assessing Adipocyte Viability and Surgeons' Work Efficiency by Comparing Different Liposuction Methods,” Plastic Reconstr. Surg. Glob. Open, 9 Pages (2023). [cited by applicant]